Skip to main content
Clinical Trials/JPRN-jRCTs041180145
JPRN-jRCTs041180145
Completed
Phase 2

A Multi-Center Phase II Study in Children and Adolescence with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia - ALL-T11

Watanebe Arata0 sites364 target enrollmentMarch 29, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Watanebe Arata
Enrollment
364
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The clinical trial for newly diagnosed T-ALL patients aged less than 25 years old cooperatively conducted by Japan Children's Cancer Study Group and Japan Adult Leukemia Study Group has been implemented. This trial was a BFM-based treatment with the intensification of nelarabine and L-asparaginase. It showed encouraging and comparable outcomes to other clinical trials with acceptable toxicities.

Registry
who.int
Start Date
March 29, 2019
End Date
November 30, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Watanebe Arata

Eligibility Criteria

Inclusion Criteria

  • 1\) diagnosis of T\-ALL (CD3\+ or cyCD3\+ and more than one is positive among CD2, CD5, CD7, CD8\)
  • 2\) age less than 25 years old
  • 3\) ECOG performance status (PS) acore of 0\-2\.However, PS scores up to 3 are permitted when the deterioration of PS is thought to be due to leukemia.
  • 4\) no history of previous chemotherapy or radiation therapy
  • 5\) sufficient hepatic and renal function satisfying the laboratory data listed below ;
  • (1\)T\-Bili: within 3x of age adjusted upper\-limit of normal range.
  • (2\)Creatinine: within 3x of age adjusted upper\-limit of normal range.
  • 6\) written informed consent obtained from patient or guardians.

Exclusion Criteria

  • 1\) Intracranial hemorrhage more than grade 3 of CTCAE v4\.0
  • 2\) uncontrolled infection, including active tuberculosis and positive of HIV antibody.
  • 3\) pregnancy or high possibility of pregnancy and giving suck woman.
  • 4\) history of congenital or acquired immunodeficiency.
  • 5\) Down syndrome.
  • 6\) QTfc, corrected by Fridericia formula as QTfc \= QT/RR cube root, is more than 0\.45 seconds.
  • 7\) any inappropriate status judged by physician.

Outcomes

Primary Outcomes

Not specified

Similar Trials